A Phase 2 interventional study of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) in Metastatic Hormone-sensitive Prostate Cancer (mHSPC), sponsored by Georgetown University. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Georgetown University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 43rd largest by planned enrollment of the 185 interventional ones that give a count, is one of 7 that started in 2026, is one of 104 in phase 2, reaches primary completion later than 23 of the 23 other live ones, and was the 191st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Charles Drew University of Medicine and Science · Sites in United States
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 131 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 39 across the 185 interventional studies. Of the 143 that completed or were terminated, 53 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 193 have an industry lead sponsor. The 10 most frequent:
Georgetown University is the lead sponsor of 292 studies on the registry; 40 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.
15 studies in Prostatic Neoplasms by Georgetown University: 4 open now, 4 under way, none of them phase 3. Of 8 finished, 2 (25%) have results posted.
Among the 15 studies in Prostatic Neoplasms by Georgetown University, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 2, and was the 15th registered.
Georgetown University’s Prostatic Neoplasms studies by the year they started, since 2002.
6 of the studies testing docetaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT06480110Rigshospitalet, DenmarkEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | 2026-12-01 |
| NCT04633252National Cancer Institute (NCI)A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | 2026-12-31 |
| NCT04015622British Columbia Cancer AgencyPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, from their registry updates:
Among Georgetown University’s 15 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, interventional, non-randomized, phase 2 study to assess oncologic outcomes of metastatic hormone-sensitive prostate cancer (mCSPC) patients who receive a risk-adapted treatment approach followed by treatment de-escalation at the Medstar Health network. A pragmatic design will be implemented in order to make the study available to patients at greatest needs from minority populations in the community. Additional assessments include quality-of-life (QoL) and sexual function changes as well as correlative studies. A maximum of 108 patients will be enrolled in this study. The investigators hypothesize that with a risk-adapted treatment approach followed by treatment de-escalation, more than 50% of patients will have radiographic progression-free survival (rPFS) at 36 months. Additionally, the investigators hypothesize that the risk-stratified de-escalation approach will result in fewer treatment-related adverse events and better QoL, compared to historical controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients with castrate sensitive prostate cancer that are eligible for standard of care (SOC) per treating physician.
a. Low risk SOC: ADT + ARPI + radiation to the prostate i. For patients with low-risk disease (defined in Section 8.1), prior treatment with ADT or ARPI for up to 8 weeks for mCSPC is permitted; however, prior treatment with docetaxel is not allowed.
b. High risk SOC: ADT + ARPI +/- docetaxel i. For patients with high-risk disease (defined in Section 8.1), prior treatment with ADT, ARPI, or docetaxel for up to 8 weeks for mCSPC is permitted.
Exclusion Criteria:
Patients who have received prior treatment with any of the following:
Patients with prior treatment with an ARPI for non- disease within 6 months of diagnosis of metastatic disease are not eligible.
a. Note: Patients who were diagnosed with metastatic disease or more than 6 months after treatment with an ARPI non-metastatic disease are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low risk patients will receive 6-month doublet therapy with Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitor (ARPI) + prostate radiation with or without radiation to metastatic sites followed by 30 months ARPI monotherapy. At a 36-month timepoint, those who maintain a prostate specific antigen (PSA) ≤ 0.2ng/mL will have the option to either discontinue treatment proceeding with active surveillance or continue on their ARPI until disease progression or intolerable toxicity. Patients who discontinue ARPI will resume ARPI and ADT when the PSA ≥ 2 ng/mL above the lowest PSA on two consecutive checks at least 1 month apart, there is evidence of progressive disease (PD) on conventional scans \[CT/MRI imaging per modified RECIST 1.1 or bone scan per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)\], clinical symptoms of progression, or if the patient prefers to continue ARPI and ADT.
Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Pathway Inhibitor (ARPI) · Radiation: Prostate Radiation
High-risk patients will receive triplet therapy with ADT + ARPI + 6 cycles of docetaxel followed by 18-months of ADT + ARPI and then 12-month ARPI monotherapy. If a patient has high-risk disease but, based on the investigator's judgment, has contraindications to docetaxel or is deemed unsuitable for it, they will receive the same treatment regimen as other high-risk patients minus the docetaxel. Then at a 36-month timepoint, those who maintain a PSA ≤ 0.2ng/mL will have the option to either discontinue treatment with active surveillance or continue ARPI until disease progression or intolerable toxicity. Patients who discontinue ARPI will resume ARPI and ADT when the PSA ≥ 2 ng/mL above the lowest PSA (nadir) on two consecutive checks at least 1 month apart, there is evidence of progressive disease (PD) on conventional scans \[CT/MRI imaging per modified RECIST 1.1 or bone scan per PCWG3\], clinical symptoms of progression, or if the patient prefers to continue ARPI and ADT.
Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Pathway Inhibitor (ARPI) · Drug: Docetaxel
ADT, Gonadotropin-releasing hormone (GnRH) agonist or antagonists, as prescribed by the treating physician.
Darolutamide is the preferred ARPI for this study; however, patients may receive abiraterone, apalutamide, or enzalutamide at the discretion of their oncologist and based on patient preference.
prostate radiation, with or without radiation to metastatic sites
Docetaxel will be administered as prescribed by the treating physician.
Also known as: Taxotere, Docivyx, Docefrez, BEIZRAY
Radiological progression-free survival (rPFS)
rPFS is defined as the time from the first dose of systemic therapy for mCSPC to the first documented radiological progression in soft tissue or bone, based on CT, MRI, or NM bone scan, using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for soft-tissue metastases and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases, or death from any cause.
Time frame: 36 months
Overall survival (OS)
OS is defined as the time from the date of treatment to death from any cause. OS at 5 years is defined as being alive at 5 years after starting of ADT.
Time frame: 5 years
rPFS using PSMA PET/CT scan combined with PSA response
This is defined at the time from the first dose of systemic therapy for mCSPC to the time to progressive disease as measured by PSMA PET/CT scan (RECIP 1.0) combined with PSA response
Time frame: 5 years
Time to initiation of subsequent antineoplastic therapy
Time to initiation of subsequent antineoplastic therapy is defined as the time from initiation of ADT to subsequent antineoplastic therapy for prostate cancer.
Time frame: 5 years
Disease progression within 5 years of starting ADT for mCSPC
The number of patients with disease progression at 5 years
Time frame: 5 years
Symptomatic skeletal event free (SSE) survival
SSE survival is defined as the time from first dose of systemic therapy for mCSPC to the first occurrence of SSE or death from any cause, whichever comes first. An SSE is defined as external beam radiation therapy (EBRT) to relieve skeletal symptoms, or new symptomatic pathologic bone fracture, or occurrence of spinal cord compression or tumor-related orthopedic surgical intervention, whichever comes first.
Time frame: 5 years
Time to pain progression
Time from start date of ADT to the first date a subject experiences a pain progression. Pain will be assessed using the PEG Scale (Pain, Enjoyment, General Activity) Questionnaire
Time frame: 5 years
Adverse Events
Number of patients with an AE that resulted in treatment discontinuation.
Time frame: 5 years
Quality-of-life changes per Functional Assessment of Cancer Therapy (FACT) Prostate Cancer Symptom Index - 17 (FACT-FPSI-17)
Patients with changes to quality of life ans sexual function as measured by National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (FACT) Prostate Cancer Symptom Index - 17 Item Version (NCCN/FACT-FPSI-17). Score rage 0 to 68, a score of "0" is a severely symptomatic patient and the highest possible score is an asymptomatic patient.
Time frame: 3 months, 6 months, 9 month, 1 year
Quality-of-life changes per Brief Pain Inventory-Short Form (BPI-SF)
Patients with changes to quality of life as measured by Brief Pain Inventory-Short Form (BPI-SF). Score range 0 to 10; a low score equals less pain severity and less pain interference, a higher score equals higher pain severity and interference.
Time frame: 3 months, 6 months, 9 month, 1 year
Development of osteoporosis
The number of patients that develope osteoporosis within 5 years on study
Time frame: 5 years
Development of osteopenia
The number of patients that develope osteopenia within 5 years on study
Time frame: 5 years
Prevalence of gynecomastia
The number of patients who develop Grade 1 to 3 Gynecomastia;
Time frame: 5 years
Start is estimated for Dec 2026; primary completion for Aug 2032, 68 months later.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 68 months is above that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel